The selective inhibition of MMP‐2 is therefore markedly important for the treatment of GBM since, after surgical resection, residual senescence cells can invade the surrounding tissue and reconstitute the tumor microenvironment (TME).[12, 13, 14] However, a systemic administration of MMP inhibitors (MMPIs) is not feasible, because of their intrinsic lack of selectivity and the associated side effects.[15, 16, 17] An effective solution consists in filling the surgical sites, after tumor resection, with a biomaterial progressively releasing in situ the appropriate MMPI.[18]. The gene discussed is MMP2; the disease is glioblastoma.